

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

RESIGNATION OF EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Consun Pharmaceutical Group Limited (the “**Company**”) announces that Ms. TANG Ning (“**Mr. Tang**”) has resigned from the position of an executive director of the Company with effect upon the conclusion of the forthcoming annual general meeting of the Company, which is expected to be held on 29 May 2020, in order to devote more time to his family.

Mr. Tang has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the shareholders of the Company.

The Board would like to take this opportunity to express its appreciation for the valuable contributions made by Mr. Tang towards the Company during his tenure of office.

By order of the Board of
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 23 March 2020

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian, Professor ZHU Quan and Mr. TANG Ning as executive directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive directors.